<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232752</url>
  </required_header>
  <id_info>
    <org_study_id>P03-6319</org_study_id>
    <nct_id>NCT00232752</nct_id>
  </id_info>
  <brief_title>Study of the 4.0mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions</brief_title>
  <official_title>A Multicenter, Non-Randomized Study of the 4.0mm Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the safety and effectiveness of the
      sirolimus-eluting Bx VELOCITYTM stent in reducing in-lesion late loss in patients with de
      novo native coronary artery lesions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is in-lesion late loss at 6 months post-procedure by QCA.</measure>
    <time_frame>6 months post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat target lesion revascularization at 30 days and 6, 9, and 12 months, and 2, 3, 4 and 5 years post-proced</measure>
    <time_frame>30 days and 6, 9, and 12 months, and 2, 3, 4 and 5 years post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic in-stent and in-lesion binary restenosis (Â³50% diameter stenosis) 6 months post-procedure by QCA.</measure>
    <time_frame>6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-lesion minimum lesion diameter (MLD) at 6 months post-procedure.</measure>
    <time_frame>6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR) at 6 and 9 months post-procedure.</measure>
    <time_frame>6 and 9 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR) at 6 and 9 months post-procedure.</measure>
    <time_frame>6 and 9 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF) at 6 and 9 months post-procedure.</measure>
    <time_frame>6 and 9 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent lumen and stent obstruction volume by intravascular ultrasound (IVUS) at post-procedure and six months in a subset of approximately 50 patients at selected centers.</measure>
    <time_frame>post-procedure and six months in a subset of approximately 50 patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success defined as achievement of a final residual diameter stenosis of &lt;50% (by QCA), using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used.</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion success defined as the attainment of &lt;50% residual stenosis (by QCA) using any percutaneous method.</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success defined as achievement of a final diameter stenosis of &lt;50% (by QCA) using any percutaneous method, without the occurrence of death, MI, or repeat revascularization of the target lesion during the hospital stay.</measure>
    <time_frame>during the hospital stay</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>4.0 CYPHER Sirolimus-Eluting Coronary Stent</intervention_name>
    <description>4.0 CYPHER Sirolimus-Eluting Coronary Stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant female patients minimum 18 years of age

          2. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society
             Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald
             Classification B&amp;C, I-II) OR patients with documented silent ischemia;

          3. Target lesions treatable with 4mm stent (visual estimate);

          4. Target lesion is 30mm in length (visual estimate);

          5. Target lesion stenosis is &gt;50% and &lt;100% (visual estimate);

        Exclusion Criteria:

          1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented
             total CK &gt;2 times normal within the preceding 24 hours and the CK and CK-MB enzymes
             remains above normal at the time of treatment;

          2. Has unstable angina classified as Braunwald III B or C, or is having a peri
             infarction;

          3. Documented Left ventricular ejection fraction 25%;

          4. Impaired renal function (creatinine &gt; 3.0 mg/dl) at the time of treatment;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauri Laura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2005</study_first_submitted>
  <study_first_submitted_qc>October 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2005</study_first_posted>
  <disposition_first_submitted>November 16, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 16, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 18, 2009</disposition_first_posted>
  <last_update_submitted>December 1, 2009</last_update_submitted>
  <last_update_submitted_qc>December 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mauri Laura, MD</name_title>
    <organization>Brigham &amp; Women's Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

